Nucleoside inhibitors of tick-borne encephalitis virusNucleoside inhibitors of Zika virusLEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cellsEnhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptorViral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 diseaseUpdate on human herpesvirus 6 biology, clinical features, and therapyMechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitroInhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agentActivities of various compounds against murine and primate polyomavirusesAntiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapyHIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulationMultidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogsEstablishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonistsMycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in miceHIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchAn Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase.Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in MiceRibavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of ValopicitabineThe Imidazopyrrolopyridine Analogue AG110 Is a Novel, Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral ReplicationCrystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse TranscriptaseApproved Antiviral Drugs over the Past 50 YearsAMD3100/CXCR4 InhibitorDiverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophilsHIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cellsThe regulation of HIV-1 transcription: molecular targets for chemotherapeutic interventionThe design of drugs for HIV and HCVPhosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood plateletsGlycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteinsQuantitative analysis of human herpesvirus 6 cell tropismDiscovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zosterNew therapeutic approaches targeted at the late stages of the HIV-1 replication cycleAllosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriCommon features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptaseKinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)tKinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-diDifferential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virusSulfonic acid polymers as a new class of human immunodeficiency virus inhibitorsSynthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents
P50
Q24276103-8829755D-0306-41E0-A498-7B3B63244829Q24278770-AC3BE012-9B14-4EAB-A284-3554EFFD5119Q24304259-1D17E7B8-213E-4FB2-BABB-4FFC1B20F406Q24314848-0886DB9B-47B7-4120-8CB2-B9CAB9F127BBQ24524292-E43AB0A4-15AA-4D87-BB3F-D0224F5D3997Q24557543-4D795BA5-1487-4350-A72D-46D5D3E8E8DFQ24650946-5195FB70-34F5-4D48-82DD-ECD9EED607B7Q24656023-1C7D91EA-227F-4B05-A88D-6DD042AC3B87Q24671713-DFA629DA-51B8-4285-B5D2-3EBC44E7AE0DQ24672068-84FBAB42-FFEE-465C-8F65-BED8B4658707Q24676438-F1470EE7-7D7C-409C-8CBB-B25DE0B869BEQ24681283-9F48F6D4-4276-4D59-B7B5-61FF57ACAC3AQ24802476-0210CFA4-5C0F-4260-8270-CCB977C68B99Q24804882-2E04C7DF-46CF-47FE-AC5B-9574DC52637BQ26746070-0164A4E8-2E1D-4C9D-92FE-9E93B90AD779Q26771734-717CEE5D-ACE6-41FD-9A76-CD4E97155590Q27472778-F3006886-29FD-496B-A4AE-1B16039ED5A0Q27473398-59E34DEE-0A3D-4CA0-B562-3E2F0F4AD6A4Q27477522-F2D5A7A0-FF0C-4BFD-92DE-04ADA628975EQ27481493-CA49E592-B83B-4E6B-B9B1-BAA4E3889113Q27657535-1617172A-3101-42AA-BC55-647F0D1DD4F2Q27755387-2A94E8AA-C2F1-45FE-B7C3-1EA72C9DB067Q28087445-A3453376-046A-42E6-9E1B-9D9BB53DA6B3Q28205971-559942C6-A11D-4DA5-911C-69D4CB284A43Q28212168-94F933D3-6A62-4A1A-8D65-DD8D7E248E8FQ28251761-348D7C00-B03D-4696-84F4-AC63CEBEEA2DQ28259321-13B46773-9BC3-4127-83CE-BEEC6D4DC2CDQ28271525-66914933-FA0F-4970-B3F6-799D5E756A1AQ28290262-69A8CE2E-5481-4BC8-B08E-A4F78BC49522Q28293267-A811EE20-BD52-4AAB-A171-F09E3D56160EQ28293880-018CBA14-819B-4C1F-BA8A-6C0BCC5949CCQ28299282-CF7639BF-1514-405B-A6A1-88A38970B32EQ28316077-0DF4700A-E0DC-45FB-87C1-65BAD67AEA6EQ28316183-3100A5D1-0619-4D78-8FE1-2732FF1A94CEQ28316200-F83510B5-830F-4349-B918-98DDDB577064Q28316228-A3AC5031-3EDC-45BC-9F0E-894E4406733DQ28316231-1EA39BD4-5F0E-4399-AF7F-E032E8ED5DD1Q28316275-BEDE83E8-13C1-46C2-84BE-58B7876A083EQ28316442-0B80A727-3DA2-4FBF-B803-9B4F486FF863Q28317878-EE45BF39-ACB8-4965-BE10-7EC8C6A7B547
P50
description
belgischer Virologe
@de
biologist, physician
@en
viroloog uit België
@nl
virólogu belxicanu
@ast
عالم فيروسات بلجيكي
@ar
name
Erik De Clercq
@en
Erik De Clercq
@ga
Erik De Clercq
@it
Erik De Clercq
@nl
Erik De Clercq
@sl
Erik De Clercq
@sq
Erik DeClercq
@es
Erik de Clercq
@ca
Erik de Clercq
@de
Erik de Clercq
@fr
type
label
Erik De Clercq
@en
Erik De Clercq
@ga
Erik De Clercq
@it
Erik De Clercq
@nl
Erik De Clercq
@sl
Erik De Clercq
@sq
Erik DeClercq
@es
Erik de Clercq
@ca
Erik de Clercq
@de
Erik de Clercq
@fr
altLabel
E De Clercq
@en
prefLabel
Erik De Clercq
@en
Erik De Clercq
@ga
Erik De Clercq
@it
Erik De Clercq
@nl
Erik De Clercq
@sl
Erik De Clercq
@sq
Erik DeClercq
@es
Erik de Clercq
@ca
Erik de Clercq
@de
Erik de Clercq
@fr